Please amend the specification as follows:

I. Please replace the "Related Applications" section of the specification at page 1, line 5 to page 2, line 2 with the following replacement section:

--**RELATED APPLICATIONS**

This application claims priority to prior filed U.S. Provisional Application Serial No. 60/397,275, filed July 19, 2002. This application also claims priority to prior filed to U.S. Provisional Application Serial No. 60/411,081, filed September 16, 2002, and prior-filed U.S. Provisional Application Serial No. 60/417490, filed October 10, 2002. This application also claims priority to prior filed to U.S. Provisional Application Serial No. 60/455777, filed March 18, 2003. In addition, this application is related to U.S. Patent Nos. 6,090,382, 6,258,562, and 6,509,015. This application is also related to ~~U.S. Patent Application Serial No. 09/801,185~~ U.S. Patent No. 7,223,394, filed March 7, 2001; U.S. Patent Application Serial No. 10/302,356, filed November 22, 2002 (now abandoned); U.S. Patent Application Serial No. 10/163657, filed June 2, 2002; and U.S. Patent Application Serial No. 10/133715, filed April 26, 2002 (now abandoned).

This application is related to U.S. utility applications ~~(Attorney Docket No. BPI-187)~~ 10/622932 entitled "Treatment of TNFα-Related Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-188) entitled "Treatment of Spondyloarthropathies Using TNFα Inhibitors," (Attorney Docket No. BPI-189)~~ 10/623076 (now abandoned) entitled "Treatment of Pulmonary Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-190)~~ 10/623065 (now abandoned) entitled "Treatment of Coronary Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-191)~~ 10/622928 (now abandoned) entitled "Treatment of Metabolic Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-192)~~ 10/623075 entitled "Treatment of Anemia Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-193)~~ 10/623035 (now abandoned) entitled "Treatment of Pain Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-194)~~ 10/622683 (now abandoned) entitled "Treatment of Hepatic Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-195)~~ 10/622205 (now abandoned) entitled "Treatment of Skin and Nail Disorders Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-196)~~ 10/622210 (now abandoned) entitled "Treatment of Vasculitides Using TNFα Inhibitors," ~~(Attorney Docket No. BPI-197)~~ 10/623318 entitled "Treatment of TNFα-Related Disorders Using TNFα Inhibitors," and PCT application ~~(Attorney Docket No. BPI-187PC)~~ PCT/US2003/022566 entitled "Treatment of TNFα-Related Disorders," all of which are filed on even date herewith. The entire contents of each of these patents and patent applications are hereby incorporated herein by reference.--

2. Please amend the sentence at page 7, lines 13-19 of the specification as follows:

-- The term "TNFα inhibitor" includes agents which inhibit TNFα. Examples of TNFα inhibitors include etanercept (~~Enbrel~~ ENBREL®, Amgen), infliximab (~~Remicade~~ REMICADE®, Johnson and Johnson), human anti-TNF monoclonal antibody adalimumab (D2E7/HUMIRA®, Abbott Laboratories), CDP 571 (Celltech), and CDP 870 (Celltech) and other compounds which inhibit TNFα activity, such that when administered to a subject suffering from or at risk of suffering from a disorder in which TNFα activity is detrimental, the disorder is treated.--

Please amend the claims as follows:

Please amend claims 1, 4, 12, 18 and 22.

Please cancel claims 2, 5-11, 13-17, 19-21, 24 and 25.

Please add new claims 26-47.

1. **(Currently Amended)** A method of treating a subject suffering from ~~a spondyloarthropathy~~ psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a human anti-TNFα ~~administering a therapeutically effective amount of a human~~ antibody, or an antigen-binding fragment thereof, ~~to the subject, wherein the antibody~~ that dissociates from human TNFα with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s^{-1} or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less, such that ~~the spondyloarthropathy~~ said PsA is treated.

2. **(Canceled)**

3. **(Currently Amended)** A method of treating a subject suffering from ~~a spondyloarthropathy~~ psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a human anti-TNFα ~~administering a therapeutically effective amount of a human~~ antibody, or an antigen-binding fragment thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.

4. **(Currently Amended)** The method of ~~any one of claims 1, 2, and 3~~ claim 1 or 3, wherein the antibody~~, or antigen-binding fragment thereof,~~ is ~~D2E7~~ adalimumab, or an antigen-binding fragment thereof.

5-11. **(Canceled)**

12. **(Currently Amended)** A method for inhibiting human TNFα activity in a human subject suffering from ~~spondyloarthropathy~~ psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a human anti-TNFα ~~administering a therapeutically effective amount of a human~~ antibody, or an antigen-binding fragment thereof, ~~to the subject, wherein the antibody~~ that dissociates from human TNFα with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s^{-1} or less, both determined by

surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1 x 10^{-7} M or less.

13-17. **(Canceled)**

18. **(Currently Amended)** A method of treating a subject suffering from ~~a spondyloarthropathy~~ psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising about 40 mg of adalimumab ~~administering a therapeutically effective amount of D2E7~~, or an antigen-binding fragment thereof, to the subject, such that ~~the spondyloarthropathy~~ said PsA is treated.

19-21. **(Canceled)**

22. **(Currently Amended)** A method of treating a subject suffering from a ~~spondyloarthropathy~~ psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising about 10-150 mg of adalimumab ~~administering a therapeutically effective amount of D2E7~~, or an antigen-binding fragment thereof, and at least one additional therapeutic agent to the subject, such that ~~the spondyloarthropathy~~ said PsA is treated.

23. **(Original)** The method of claim 22, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.

24-25. **(Canceled)**

26. **(New)** A method for inhibiting human TNFα activity in a human subject suffering from psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a human anti-TNFα antibody, or an antigen-binding fragment thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.

27. **(New)** A method for inhibiting human TNFα activity in a human subject suffering from psoriatic arthritis (PsA) comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of adalimumab.

28. **(New)** The method of claim 1, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

29. **(New)** The method of claim 3, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

30. **(New)** The method of claim 4, wherein the unit dosage form comprises 20-80 mg of adalimumab.

31. **(New)** The method of claim 12, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

32. **(New)** The method of claim 26, wherein the unit dosage form comprises 20-80 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

33. **(New)** The method of claim 27, wherein the unit dosage form comprises 20-80 mg of adalimumab.

34. **(New)** The method of claim 1, wherein the unit dosage form comprises about 40 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

35. **(New)** The method of claim 3, wherein the unit dosage form comprises about 40 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

36. **(New)** The method of claim 12, wherein the unit dosage form comprises about 40 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

37. **(New)** The method of claim 26, wherein the unit dosage form comprises about 40 mg of the human anti-TNFα antibody, or antigen-binding fragment thereof.

38. **(New)** The method of claim 27, wherein the unit dosage form comprises about 40 mg of adalimumab.

39. **(New)** The method of claim 1, further comprising administering to the subject at least one additional therapeutic agent.

40. **(New)** The method of claim 39, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.

41. **(New)** The method of claim 3, further comprising administering to the subject at least one additional therapeutic agent.

42. **(New)** The method of claim 41, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.

43. **(New)** The method of claim 12, further comprising administering to the subject at least one additional therapeutic agent.

44. **(New)** The method of claim 43, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.

45. **(New)** The method of claim 26, further comprising administering to the subject at least one additional therapeutic agent.

46. **(New)** The method of claim 45, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.

47. **(New)** The method of claim 27, further comprising administering to the subject at least one additional therapeutic agent.

48. **(New)** The method of claim 47, wherein the additional therapeutic agent is selected from the group consisting of ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, and diclofenac.